The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

V.C.J. van de Vlasakker; R.J. Lurvink; P.H. Cashin; W. Ceelen; M. Deraco; D. Goere; S. Gonzalez-Moreno; K. Lehmann; Y. Li; B. Moran; D.L. Morris; P. Piso; C.A. Quadros; B. Rau; S.P. Somashekhar; A. Sommariva; K. van der Speeten; J. Spiliotis; P.H. Sugarbaker; M.C.C. Teo; V.J. Verwaal; Y. Yonemura; O. Glehen; I.H.J.T. de Hingh

doi:10.1016/j.ejso.2021.05.023

The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

V.C.J. van de Vlasakker, R.J. Lurvink, P.H. Cashin, W. Ceelen, M. Deraco, D. Goere, S. Gonzalez-Moreno, K. Lehmann, Y. Li, B. Moran, D.L. Morris, P. Piso, C.A. Quadros, B. Rau, S.P. Somashekhar, A. Sommariva, K. van der Speeten, J. Spiliotis, P.H. Sugarbaker, M.C.C. TeoV.J. Verwaal, Y. Yonemura, O. Glehen, I.H.J.T. de Hingh^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction: The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. Materials and methods: CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. Results: The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. Conclusion: The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated. (c) 2021 Published by Elsevier Ltd.

Original language	English
Pages (from-to)	2888-2892
Number of pages	5
Journal	European Journal of Surgical Oncology
Volume	47
Issue number	11
DOIs	https://doi.org/10.1016/j.ejso.2021.05.023
Publication status	Published - 1 Nov 2021

Keywords

CRS-HIPEC
HIPEC
Colorectal peritoneal metastases
PRODIGE 7
CYTOREDUCTION

Access to Document

10.1016/j.ejso.2021.05.023

Cite this

van de Vlasakker, V. C. J., Lurvink, R. J., Cashin, P. H., Ceelen, W., Deraco, M., Goere, D., Gonzalez-Moreno, S., Lehmann, K., Li, Y., Moran, B., Morris, D. L., Piso, P., Quadros, C. A., Rau, B., Somashekhar, S. P., Sommariva, A., van der Speeten, K., Spiliotis, J., Sugarbaker, P. H., ... de Hingh, I. H. J. T. (2021). The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology, 47(11), 2888-2892. https://doi.org/10.1016/j.ejso.2021.05.023

@article{8b74ec0163f143caa119b392358bf0fc,

title = "The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)",

abstract = "Introduction: The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. Materials and methods: CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. Results: The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. Conclusion: The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated. (c) 2021 Published by Elsevier Ltd.",

keywords = "CRS-HIPEC, HIPEC, Colorectal peritoneal metastases, PRODIGE 7, CYTOREDUCTION",

author = "{van de Vlasakker}, V.C.J. and R.J. Lurvink and P.H. Cashin and W. Ceelen and M. Deraco and D. Goere and S. Gonzalez-Moreno and K. Lehmann and Y. Li and B. Moran and D.L. Morris and P. Piso and C.A. Quadros and B. Rau and S.P. Somashekhar and A. Sommariva and {van der Speeten}, K. and J. Spiliotis and P.H. Sugarbaker and M.C.C. Teo and V.J. Verwaal and Y. Yonemura and O. Glehen and {de Hingh}, I.H.J.T.",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.ejso.2021.05.023",

language = "English",

volume = "47",

pages = "2888--2892",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "ELSEVIER SCI LTD",

number = "11",

}

van de Vlasakker, VCJ, Lurvink, RJ, Cashin, PH, Ceelen, W, Deraco, M, Goere, D, Gonzalez-Moreno, S, Lehmann, K, Li, Y, Moran, B, Morris, DL, Piso, P, Quadros, CA, Rau, B, Somashekhar, SP, Sommariva, A, van der Speeten, K, Spiliotis, J, Sugarbaker, PH, Teo, MCC, Verwaal, VJ, Yonemura, Y, Glehen, O & de Hingh, IHJT 2021, 'The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)', European Journal of Surgical Oncology, vol. 47, no. 11, pp. 2888-2892. https://doi.org/10.1016/j.ejso.2021.05.023

The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). / van de Vlasakker, V.C.J.; Lurvink, R.J.; Cashin, P.H. et al.
In: European Journal of Surgical Oncology, Vol. 47, No. 11, 01.11.2021, p. 2888-2892.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

AU - van de Vlasakker, V.C.J.

AU - Lurvink, R.J.

AU - Cashin, P.H.

AU - Ceelen, W.

AU - Deraco, M.

AU - Goere, D.

AU - Gonzalez-Moreno, S.

AU - Lehmann, K.

AU - Li, Y.

AU - Moran, B.

AU - Morris, D.L.

AU - Piso, P.

AU - Quadros, C.A.

AU - Rau, B.

AU - Somashekhar, S.P.

AU - Sommariva, A.

AU - van der Speeten, K.

AU - Spiliotis, J.

AU - Sugarbaker, P.H.

AU - Teo, M.C.C.

AU - Verwaal, V.J.

AU - Yonemura, Y.

AU - Glehen, O.

AU - de Hingh, I.H.J.T.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Introduction: The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. Materials and methods: CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. Results: The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. Conclusion: The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated. (c) 2021 Published by Elsevier Ltd.

AB - Introduction: The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented at the 2018 ASCO meeting showing that 30 min oxaliplatin-based HIPEC did not improve overall survival. The current study investigated the impact of PRODIGE 7 on the worldwide practice of CRS and HIPEC. Materials and methods: CRS-HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning the current CRS-HIPEC practice in their hospital and country, and were asked to appraise the effect of PRODIGE 7. Results: The survey was completed by 18/19 experts. Although their personal opinions of CRS-HIPEC were barely influenced by PRODIGE 7, they reported a substantial impact on daily practice. This included a switch towards Mitomycin-C based HIPEC-regimens and prolongation of HIPEC perfusion time, a reduction in the number of referrals from non-HIPEC centers, a reduction in national consensus, the removal of HIPEC from national guidelines, and a reduced reimbursement rate. Conclusion: The PRODIGE 7 has had a major impact on the practice of CRS-HIPEC for CPM worldwide. HIPEC remains an attractive option with potential for control and eradication of disease and further studies into the optimal HIPEC-regimen are urgently needed. Meanwhile, given the complexity of the treatment of patients with CPM, and the proven benefits of optimal CRS, referral of patients with potentially resectable CPM to expert centers is recommended whilst the precise role of HIPEC is further evaluated. (c) 2021 Published by Elsevier Ltd.

KW - CRS-HIPEC

KW - HIPEC

KW - Colorectal peritoneal metastases

KW - PRODIGE 7

KW - CYTOREDUCTION

U2 - 10.1016/j.ejso.2021.05.023

DO - 10.1016/j.ejso.2021.05.023

M3 - Article

C2 - 34020808

SN - 0748-7983

VL - 47

SP - 2888

EP - 2892

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 11

ER -

van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goere D et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology. 2021 Nov 1;47(11):2888-2892. doi: 10.1016/j.ejso.2021.05.023